Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours

• Published in: Endocrine oncology Vol. 5; no. 1; p. e250005
• Main Authors: Gamage, Isuru, Boehm, Emma, Ghosh, Gaurav, Kong, Grace, Michael, Michael, Wong, HuiLi, Piercey, Oliver, Sachithanandan, Nirupa
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.01.2025; Bioscientifica
• Subjects: Case Report; hypoglycaemia; insulinoma; metastatic insulinoma; metastatic neuroendocrine tumour; neuroendocrine neoplasms; neuroendocrine tumour; peptide receptor radionuclide therapy; radionuclide therapy; somatostatin analogue; neuroendocrine neoplasms; neuroendocrine tumour; radionuclide therapy; hypoglycaemia; metastatic insulinoma; peptide receptor radionuclide therapy; insulinoma; metastatic neuroendocrine tumour; somatostatin analogue

Somatostatin analogues (SSA) are used in the management of patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) to control hormone secretion and tumour growth. SSA can paradoxically worsen or unmask hypoglycaemia in patients with insulinoma by inhibiting counter-regulator...